nocturnal enuresis. Nonorganic enuresis
Conditions
Interventions
Intervention 1: Intra nasal Desmopressin 1 puff/Qhs plus Tolterodine 1mg daily during 6 month. Intervention 2: Intra nasal Desmopressin 1 puff/Qhs plus solifenacin 5 mg daily during 6 month.
Treatment - Drugs
Intra nasal Desmopressin 1 puff/Qhs plus Tolterodine 1mg daily during 6 month
Intra nasal Desmopressin 1 puff/Qhs plus solifenacin 5 mg daily during 6 month
Sponsors
Vice Chancellor for Research and Technology of Ahvaz Jundishapur University of Medical Sciences
Eligibility
Sex/Gender
All
Age
5 Years to 15 Years
Inclusion criteria
Inclusion criteria: children with primary nucturnal enurises
Exclusion criteria
Exclusion criteria: patients with neurogenic bladder CNS disorders urine-concentrating defects
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response to treatment. Timepoint: Monthly regarding during 6 months. Method of measurement: According things that their parents and children say, patients will be classified to full response (complete dry), good response (90 to 99% reduction in wet nights), and partial response (50 to 90% reduction). | — |
Secondary
| Measure | Time frame |
|---|---|
| Abdominal pain. Timepoint: Monthly during 6 months. Method of measurement: Clinical symptoms.;Vomiting. Timepoint: Monthly during 6 months. Method of measurement: Clinical symptoms. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactSeyedeh Parvin Mosavi Ghanavati
Ahvaz University of Medical Sciences
Outcome results
None listed